News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
November 2017
-
Media ReleaseNovartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy- Presentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer- New MONALEESA-2 analyses focused…
-
Media ReleaseNovartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
-
Media ReleaseNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Media ReleaseNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
-
Media ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Media ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media ReleaseNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage- Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study(1)- PsA can lead to reduced mobility…
-
Media ReleaseNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media ReleaseNovartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease- Primary results of pivotal Kymriah™ Phase II JULIET study in relapsed/refractory DLBCL- Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle…
-
Media ReleaseNovartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
October 2017
-
Media ReleaseNovartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a- PARADIGMS data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections(1)- Currently there are no disease-modifying…
-
Media ReleaseNovartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
Pagination
- ‹ Previous page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- …
- 56
- › Next page